Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bethany Whitesell

Optometrist Springfield, MO Doctor of Optometry

NPI 1861486946 CMS profile 957271

1531 East Bradford Parkway Ste 100, Springfield, MO 65804

Open in the dashboard

General payments

$1,724

27 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bethany Whitesell of Springfield, MO is reported in the CMS Open Payments database as having received $1,724 across 27 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $308 4
2024 General $214 4
2023 General $247 4
2022 General $347 3
2021 General $353 5
2020 General $134 4
2019 General $122 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bethany Whitesell
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Bethany Whitesell were reported at $308. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Bethany Whitesell Optometrist median Middle half National median
2019 $122 $159 $67–$371 $163
2020 $134 $72 $29–$165 $114
2021 $353 $125 $46–$292 $132
2022 $347 $162 $66–$374 $149
2023 $247 $177 $72–$406 $160
2024 $214 $188 $77–$427 $164
2025 $308 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $430 4 payments
  2. Johnson & Johnson Surgical Vision, Inc. $271 6 payments
  3. Horizon Therapeutics plc $246 3 payments
  4. Glaukos Corporation $168 2 payments
  5. Sight Sciences, Inc. $150 1 payment
  6. RxSight Inc $145 1 payment
  7. Sun Pharmaceutical Industries Inc. $142 4 payments
  8. Bausch & Lomb Americas Inc. $131 3 payments
  9. Allergan Inc. $15 1 payment
  10. Lensar, Inc. $13 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,724 27 payments
Products named General payments · program years 2019–2025
  1. AcrySof IQ PanOptix UV IOL $262 2 payments
  2. TEPEZZA $246 3 payments
  3. TEARCARE SYSTEM $150 1 payment
  4. RXSIGHT CONTACT LENS $145 1 payment
  5. RXSIGHT INJECTOR CARTRIDGE $145 1 payment
  6. RXSIGHT INJECTOR HANDPIECE $145 1 payment
  7. RXSIGHT LIGHT DELIVERY DEVICE (LDD) $145 1 payment
  8. LIGHT ADJUSTABLE LENS (LAL) $145 1 payment
  9. AcrySof IQ VIVITY $143 1 payment
  10. Cequa $142 4 payments
  11. Other $713 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,988

Median for Optometry: 120

Drug cost

$45,129

Median for Optometry: $8,864

Branded share of claims

19.1%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 19 $9,663
Prednisolone Acetate Generic 329 $8,343
Combigan Brimonidine Tartrate/Timolol Brand 29 $6,529
Fluorometholone Generic 68 $3,841
Latanoprost Generic 503 $3,636
Ketorolac Tromethamine Generic 144 $2,835
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 255 $2,821
Timolol Maleate Generic 216 $1,657
Ofloxacin Generic 140 $1,491
Brimonidine Tartrate Generic 144 $1,067

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$70,740

Medicare's payments for the services billed

Medicare patients

643

Average age 76

Services billed

1,447

392 women, 251 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 35%
Ischemic heart disease 27%
Chronic kidney disease 26%
COPD 21%
Atrial fibrillation 19%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record